OncLive® On Air
Episodes
S7 Ep47: FDA Approval Insights: Teclistamab in Relapsed/Refractory Multiple Myeloma
14 Nov 2022
Contributed by Lukas
Dr Garfall discusses the FDA approval of teclistamab in relapsed/refractory multiple myeloma, key efficacy and safety data from the MajesTEC-1 trial, ...
S7 Ep46: Lunning Lends Insight on Pivotal Data From Pan Pacific Lymphoma 2022
10 Nov 2022
Contributed by Lukas
In this inaugural episode, Dr Lunning details important findings to come out of the Pan Pacific Lymphoma Conference, including results evaluating prop...
S7 Ep45: Sauter and Hill Talk Through CAR T Cell Sequencing and Access in Lymphomas
07 Nov 2022
Contributed by Lukas
Drs Sauter and Hill discuss the use of CAR T-cell therapy in patients with lymphomas, the potential for allogeneic CAR T cells, and ways to expand acc...
S7 Ep44: FDA Approval Insights: Futibatinib in FGFR2-Positive Cholangiocarcinoma
03 Nov 2022
Contributed by Lukas
Dr Goyal discusses the FDA approval of futibatinib in FGFR2-positive cholangiocarcinoma, key safety data from the FOENIX*-CCA2 trial, and the importan...
S7 Ep43: Thymic Cancer Experts Discuss the Latest Data, Need for More Research Funding
31 Oct 2022
Contributed by Lukas
Drs Giaccone and He discuss the implications of their thymic cancer research, the importance of combining immunotherapy and anti-angiogenesis agents t...
S7 Ep42: Mikhael and Cole Share Insights on Culturally Relevant Myeloma Care
27 Oct 2022
Contributed by Lukas
Drs Mikhael and Cole discuss ways to help reduce disparities in myeloma by delivering culturally relevant care and highlight the importance of impleme...
S7 Ep41: FDA Approval Insights: Sodium Thiosulfate in Cisplatin-Treated Pediatric Solid Tumors
24 Oct 2022
Contributed by Lukas
Dr Shah discusses the FDA approval of sodium thiosulfate in pediatric patients with solid tumors treated with cisplatin, key efficacy and safety data ...
S7 Ep40: Leukemia Experts Discuss Early Career Growth, Mentorship, and Gender Bias in Academia
20 Oct 2022
Contributed by Lukas
Drs DiNardo, Wang, and Altman discuss the challenges they faced in their early careers, the rollout of molecular profiling and targeted therapy in the...
S7 Ep39: Community Perspectives on Integrating and Interpreting Molecular Testing Results in NSCLC
17 Oct 2022
Contributed by Lukas
Drs Ramkumar and Morganstein discuss the challenges they face with integrating and organizing molecular testing results into electronic medical record...
S7 Ep38: FDA Approval Insights: Selpercatinib in RET Fusion–Positive Solid Tumors
13 Oct 2022
Contributed by Lukas
Dr Subbiah discusses the significance of the FDA approval of selpercatinib in RET fusion–positive non–small cell lung cancer, thyroid cancer, and ...
S7 Ep37: Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
10 Oct 2022
Contributed by Lukas
Dr Brentjens discusses targeting the “enigmatic” GPRC5D protein, safety results with MCARH109, and the appropriate sequencing for the agent.
S7 Ep36: Velcheti Discusses Mobile Telehealth-Based Research to Close Cancer Care Gaps
06 Oct 2022
Contributed by Lukas
Dr Velcheti discusses planned research into whether mobile technology services can improve patient outcomes for underserved and underrepresented patie...
S7 Ep35: FDA Approval Insights: Durvalumab Plus Gemcitabine and Cisplatin in Biliary Tract Cancer
03 Oct 2022
Contributed by Lukas
Dr Oh discusses the FDA approval of durvalumab plus gemcitabine and cisplatin in biliary tract cancer, the tolerability of the regimen, and the import...
S7 Ep34: Shepard Discusses Symptoms, Management, and Future Directions in Desmoid Tumors
29 Sep 2022
Contributed by Lukas
Dr Shepard discusses the unpredictable course of desmoid tumors, the use of TKIs for these tumors, and findings from 2 trials presented at the 2022 ES...
S7 Ep33: Deol on the Importance of a Well-Rounded Fellowship Experience
26 Sep 2022
Contributed by Lukas
Dr Deol discusses what he wants his trainees to take from the fellowship program he directs, how his colleagues help fellows find jobs, and how he hel...
S7 Ep32: Patel Provides Insight Into Post-Transplant Complications in Myeloid Disorders
22 Sep 2022
Contributed by Lukas
Dr Patel discusses post-transplant complications in myeloid disorders, the prevalence of these complications, and the most common ones that may arise,...
S7 Ep31: FDA Approval Insights: Pemigatinib in FGFR1-Rearranged Myeloid/Lymphoid Neoplasms
19 Sep 2022
Contributed by Lukas
Dr Verstovsek discusses the FDA approval of pemigatinib in myeloid/lymphoid neoplasms with FGFR1 rearrangements, the transformative effects of pemigat...
S7 Ep30: Leal Sheds Light on Symptoms and Treatment of Lambert-Eaton Myasthenic Syndrome
15 Sep 2022
Contributed by Lukas
Dr Leal discusses the symptoms commonly associated with Lambert-Eaton Myasthenic Syndrome, the prevalence of this disorder in concurrence with underly...
S7 Ep29: Elamin Elaborates on Poziotinib in EGFR Exon 20–Mutant NSCLC
12 Sep 2022
Contributed by Lukas
Dr Elamin discusses results from a phase 2 study of poziotinib efficacy in EGFR exon 20–mutant non–small cell lung cancer and highlights the agent...
S7 Ep28: Chen Discusses Diagnosis, Management, and Disparities in Cutaneous T-cell Lymphoma
08 Sep 2022
Contributed by Lukas
Dr Chen details the findings from a study of patients with transformed cutaneous T-cell lymphoma, gives her perspective on findings from the FLASH tri...
S7 Ep27: FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Low Unresectable or Metastatic Breast Cancer
05 Sep 2022
Contributed by Lukas
Dr Modi discusses the significance of the FDA approval of trastuzumab deruxtecan in metastatic HER2-low breast cancer, pivotal efficacy and safety dat...
S7 Ep27: Iams and Shah Break Down Lambert-Eaton Myasthenic Syndrome in SCLC and Other Neuroendocrine Cancers
01 Sep 2022
Contributed by Lukas
Drs Iams and Shah discuss the process of diagnosing Lambert-Eaton myasthenic syndrome in neuroendocrine cancers, how the condition affects patient pro...
S7 Ep26: Bekaii-Saab, George, and von Mehren Discuss Pivotal Findings in GIST, TGCT, and RAS/RAF–Mutated Solid Tumors
29 Aug 2022
Contributed by Lukas
Drs Bekaii-Saab, George, and von Mehren discuss key efficacy data and patient-reported outcomes from the INTRIGUE trial, the rationale for a phase 1/2...
S7 Ep25: FDA Approval Insights: Trastuzumab Deruxtecan in HER2-Mutant NSCLC
25 Aug 2022
Contributed by Lukas
Dr Levy discusses the significance of the FDA approval of trastuzumab deruxtecan in HER2-mutant NSCLC, the pivotal efficacy and safety data from the D...
S7 Ep24: Petrylak Provides Insight Into Testing, Multidisciplinary Management in Prostate and Bladder Cancer
22 Aug 2022
Contributed by Lukas
Dr Petrylak discusses current issues with genetic testing and disease management in prostate and bladder cancer, some of the reasons for poor testing ...
S7 Ep24: Goldberg and Sussman Dissect Disparities in Gastric Cancer Mortality Rates
18 Aug 2022
Contributed by Lukas
Drs Goldberg and Sussman discuss key findings from their research on rates of gastrointestinal mortality, the factors that could contribute to these d...
S7 Ep23: FDA Approval Insights: Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
15 Aug 2022
Contributed by Lukas
Dr Berchuck discusses the effects of treatment intensification with darolutamide in men with metastatic hormone-sensitive prostate cancer, the signifi...
S7 Ep22: Katz Considers the Role of Neoadjuvant Chemoradiation in Borderline Resectable Pancreatic Cancer
11 Aug 2022
Contributed by Lukas
Dr Katz discusses the implications of a recently published phase 2 study investigating neoadjuvant mFOLFIRINOX with or without hypofractionated radiat...
S7 Ep21: Leukemia Experts Reflect on Defining Moments as Women in the Field
08 Aug 2022
Contributed by Lukas
Drs Luger, Roboz, and Stock discuss the issues that were most prominent in leukemia treatment when they began their careers and what motivated them to...
S7 Ep20: Gradishar Stresses the Importance of Accurately Defining Breast Cancer Subtypes
04 Aug 2022
Contributed by Lukas
Dr Gradishar emphasizes the importance of defining metastatic breast cancer subtypes, the implications of molecular testing and genetics on treatment ...
S7 Ep19: Research Reflections: Subbiah Reviews Striking ASCO 2022 Data Across Oncology
01 Aug 2022
Contributed by Lukas
Dr Subbiah discusses findings from 4 presentations that stood out to him from the 2022 ASCO Annual Meeting: phase 2 data (NCT04165772) demonstrating a...
S7 Ep18: FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL
28 Jul 2022
Contributed by Lukas
Dr Ghosh discusses the FDA approval of lisocabtagene maraleucel in large B-cell lymphoma, pivotal efficacy and safety data from the phase 3 TRANSFORM ...
S7 Ep17: Wagner Weighs In On Research and Development in Angiosarcoma
25 Jul 2022
Contributed by Lukas
Dr Wagner talks about the struggle to investigate angiosarcoma, the ways research cooperatives have had recent success in driving the science forward,...
S7 Ep16: FDA Approval Insights: Dabrafenib Plus Trametinib for BRAF V600E–Mutated Unresectable or Metastatic Solid Tumors
21 Jul 2022
Contributed by Lukas
Dr Subbiah highlights the significance of the FDA approval of dabrafenib and trametinib in adult and pediatric patients at least 6 years of age with B...
S7 Ep15: Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer
18 Jul 2022
Contributed by Lukas
Dr Monk discusses pertinent efficacy and safety data from the ATHENA-MONO trial, which evaluated first-line maintenance treatment with rucaparib in pa...
S7 Ep14: Jain Discusses the Driving Forces of Gender Inequities in Medicine
14 Jul 2022
Contributed by Lukas
Dr Jain discusses an article she authored, titled “We’re Running Up the Wrong Side of the Escalator,” which confronts systemic and structural ob...
S7 Ep13: Spiess Shares the Importance of Comprehensive, Multidisciplinary Care in Penile Cancer
11 Jul 2022
Contributed by Lukas
Dr Spiess talks about taking part in an international consortium that seeks to establish a standard treatment for penile cancer, the ways shame interf...
S7 Ep12: Research Reflections: Tarantino Talks Through the Implications of ASCO 2022 Data in Breast Cancer
07 Jul 2022
Contributed by Lukas
Dr Tarantino discusses practice-changing findings in breast cancer and emphasizes the ways in which positive study data can improve the breast cancer ...
S7 Ep11: Duma Discusses the Unique Challenges of Women With Lung Cancer (Continued)
04 Jul 2022
Contributed by Lukas
Dr Duma discusses improving diversity in trials and in oncology providers, how the oncology field fails women in general and women of color in particu...
S7 Ep10: Duma Discusses the Unique Challenges of Women With Lung Cancer
30 Jun 2022
Contributed by Lukas
Dr Duma discusses the leading causes of lung cancer in women, the ongoing failure to screen a sufficient number of women for lung cancer, and how gend...
S7 Ep9: Leukemia Pioneers Chronicle Career Experiences and Milestones
27 Jun 2022
Contributed by Lukas
Drs Karp, Raza, and Le Beau discuss challenges they faced in their early careers as women in leukemia, the ways they overcame those obstacles, and the...
S7 Ep8: Khan Casts Light on Disparities in Surgical Care of GI Tract Cancer
23 Jun 2022
Contributed by Lukas
Dr Khan expands on key data found on racial disparities in surgical outcomes for gastrointestinal tract cancer and addresses the need to reduce the ga...
S7 Ep7: Wise Summarizes Survival Data From ARASENS and PEACE-1 in Prostate Cancer
20 Jun 2022
Contributed by Lukas
Dr Wise highlights how intensified treatment with doublet or triplet therapy can lead to better long-term outcomes in prostate cancer, potential treat...
S7 Ep6: Lee Lays Out Treatment Developments in Non–Clear Cell RCC
16 Jun 2022
Contributed by Lukas
Dr Lee highlights the latest treatment developments in non–clear cell renal cell carcinoma, emphasizes the need for more precise classification of t...
S7 Ep5: Ueno Underscores the Importance of Accurate Diagnoses and Novel Treatments in IBC
13 Jun 2022
Contributed by Lukas
Dr Ueno discusses the challenges of diagnosing inflammatory breast cancer, the unmet need for new agents to treat patients with the disease, and the c...
S7 Ep4: Hua Highlights Innovative Research With Immunotherapy in NETs
09 Jun 2022
Contributed by Lukas
Dr Hua talks about the unmet need in neuroendocrine tumors (NETs), explains the difficulty of detecting NETs, and highlights his study findings evalua...
S7 Ep3: Jefferson Faculty Highlight COVID-19-Induced Disparities in Older Patients With Cancer
06 Jun 2022
Contributed by Lukas
Chapman, Swartz, Rhodes, Nightingale, and Denton highlight the evolution of Jefferson Health’s Senior Adult Oncology Center, the unique needs of old...
S7 Ep2: Abid Accounts for the Efficacy of a Third SARS-CoV-2 Vaccine Among Transplant, CAR T-Cell, and BiTE Recipients
02 Jun 2022
Contributed by Lukas
Dr Abid discusses a review paper, published in Cancer Cell, that evaluated determinants of response to SARS-CoV-2 vaccines in patients who underwent a...
S7 Ep1: Karmanos Faculty Share Experiences and Career Insights as Women in Oncology
30 May 2022
Contributed by Lukas
Drs Mamdani, Assad, and Robinette discuss the changes in the culture of oncology today compared with when they first started their careers, the challe...
S6 Ep50: Tarantino Previews Exciting Research in HER2-Low Breast Cancer
26 May 2022
Contributed by Lukas
Dr Tarantino provides background on the categorization of HER2-low disease in breast cancer, issues with standardization and interpretation, historica...
S6 Ep49: Taylor Provides Insight Into Pirtobrutinib Resistance in CLL
23 May 2022
Contributed by Lukas
Dr Taylor discusses the significance of BTK inhibition in chronic lymphocytic leukemia, describes the key objectives of, and methods used, for the gen...
S6 Ep48: Pro Presents Interim Results of PRIMO in Peripheral T-Cell Lymphoma
19 May 2022
Contributed by Lukas
Dr Pro outlines the current role of duvelisib in peripheral T-cell lymphoma (PTCL), reviews some key adverse effects associated with the agent, and wa...
S6 Ep47: Pal Discusses Eye-Catching ASCO GU Data in RCC
16 May 2022
Contributed by Lukas
Dr Pal walks us through research presented at the 2022 Genitourinary Cancers Symposium, including data from the TIVO-3 trial (NCT02627963) and finding...
S6 Ep46: Pegram Expounds on Exciting Developments in HER2+ Metastatic Breast Cancer
12 May 2022
Contributed by Lukas
Dr Pegram discusses treatment sequencing in metastatic HER2-positive breast cancer, recent updates to the National Comprehensive Cancer Network guidel...
S6 Ep45: Cusnir on the Benefits of SIR-Spheres® Y-90 Resin Microspheres in mCRC
09 May 2022
Contributed by Lukas
Dr Cusnir reviews the benefits of isolating the liver in early colorectal cancer (CRC) treatment, how patients have tolerated Y-90 therapy, and situat...
S6 Ep44: Borgen Recommends Revamping Peer Review for a Post-COVID-19 World
05 May 2022
Contributed by Lukas
Dr Borgen recaps a presentation he made at the 2022 Miami Breast Cancer Conference highlighting the flaws with preprints, outlining his recommendation...
S6 Ep43: FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma
02 May 2022
Contributed by Lukas
Dr Lipson discusses the significance of the regulatory decision for relatlimab and nivolumab, updated data from the RELATIVITY-047 trial, adverse effe...
S6 Ep42: Jabbour Highlights New Data With Asciminib and Ponatinib in CML
28 Apr 2022
Contributed by Lukas
Dr Jabbour discusses updates from the 2021 ASH Annual Meeting and Exposition in chronic myeloid leukemia, including findings from the phase 3 ASCEMBL ...
S6 Ep41: Bardia Reflects on Important Data in HER2+ Breast Cancer
21 Apr 2022
Contributed by Lukas
Dr Bardia discusses data from DESTINY-Breast03 (NCT03529110), HER2CLIMB (NCT02614794), and NALA (NCT01808573), important findings that were presented ...
S6 Ep40: D'Abreo Addresses AEs in Metastatic Breast Cancer Care
14 Apr 2022
Contributed by Lukas
Dr D’Abreo discusses adverse effects such as fatigue, nausea and vomiting, and interstitial lung disease, shares advice on establishing an open chan...
S6 Ep39: Tripathy on Treating HER2+ Breast Cancer With Leptomeningeal Metastasis
07 Apr 2022
Contributed by Lukas
Dr Tripathy explains the rationale for the TBCRC049 trial, the challenges of investigating a disease that appears in less than 5% of patients with bre...
S6 Ep38: FDA Approval Insights: Pacritinib in Myelofibrosis
31 Mar 2022
Contributed by Lukas
Dr Mesa discusses the data that led to the FDA approval of pacritinib, toxicities clinicians should be aware of when prescribing the JAK inhibitor, an...
S6 Ep37: Research Reflections: Barzi Reviews CRC Updates From ASCO GI 2022
24 Mar 2022
Contributed by Lukas
Dr Barzi discusses data from the ACCENT and RESPECT trials evaluating the value of oxaliplatin for patients with colorectal cancer, results from an in...
S6 Ep36: Lyle and Patel Examine Diagnostic and Management Paradigms in MDS
17 Mar 2022
Contributed by Lukas
Drs Lyle and Patel review some of the challenges associated with the diagnosis and management of myelodysplastic syndromes, the current treatment land...
S6 Ep35: Ross Reflects on Surgical Advances and Changing Trends in CRC
10 Mar 2022
Contributed by Lukas
Dr Ross shares his advice to health care professionals regarding the detection and treatment of patients with colon cancer, unmet needs for this patie...
S6 Ep35: Hurvitz Reviews Pivotal Data From 2021, Previews Year Ahead in HER2+ Metastatic Breast Cancer
03 Mar 2022
Contributed by Lukas
Dr Hurvitz sheds light on shifts in practice patterns in HER2-positive breast cancer in light of data that emerged in 2021, remaining questions regard...
S6 Ep34: Jain Talks Patient Management, Dosing, and Toxicity Mitigation With Frontline PARP Maintenance in Ovarian Cancer
24 Feb 2022
Contributed by Lukas
Dr Jain discusses the current utility of frontline maintenance therapy in advanced ovarian cancer, dosing strategies with PARP inhibitors, and managem...
S6 Ep28: Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
17 Feb 2022
Contributed by Lukas
Dr Milhem discusses the unique mechanism of action and delivery method of RP1, which is being evaluated in the IGNYTE trial for patients with solid tu...
S6 Ep33: Cleveland Clinic Faculty Speak to Shifting Standards in Hematologic Malignancies
10 Feb 2022
Contributed by Lukas
We had the pleasure of speaking with faculty from an OncLive® Institutional Perspectives in Cancer webinar on hematologic malignancies, hosted in par...
S6 Ep32: Simon Shares Steps Towards Bridging Clinical Trial Disparities in Cancer
07 Feb 2022
Contributed by Lukas
Melissa A. Simon, MD, MPH, discusses unmet needs regarding clinical trials for underserved populations with cancer, highlights the key objectives of t...
S6 Ep31: Rare Cancers Report: Pediatric Neuroblastoma
03 Feb 2022
Contributed by Lukas
Dr Furman discussed the rarity of pediatric neuroblastoma, treatment options and expected outcomes for patients, and ongoing clinical trials in this s...
S6 Ep30: Ramchandren Reviews the Rationale to Further Evaluate CLR 131 in Waldenström Macroglobulinemia
31 Jan 2022
Contributed by Lukas
Dr Ramchandren discusses current treatment options for patients with Waldenström macroglobulinemia who have limited response to other therapies, the ...
S6 Ep29: Sorting Through Sexism, Guilt, and Motherhood in Medicine
27 Jan 2022
Contributed by Lukas
Drs Garg, Outlaw-Evans, and Farrington discuss their experiences as women in oncology, changes they have observed in the culture of medicine, and thei...
S6 Ep27: Wang Reflects on Ibrutinib’s Role and Emerging Research in MCL Management
20 Jan 2022
Contributed by Lukas
Dr Wang discusses the clinical experience with ibrutinib in mantle cell lymphoma, its present role in the management of MCL, and ongoing research that...
S6 Ep26: Research Reflections: Coombs Provides Insight Into Key ASH Abstracts in CLL
17 Jan 2022
Contributed by Lukas
Dr Coombs discusses research that was presented at the 2021 ASH Annual Meeting and Exposition in chronic lymphocytic leukemia, including that with cov...
S6 Ep25: Basu on Getting Ahead of the Shadow Curve of COVID-19 in Oncology
13 Jan 2022
Contributed by Lukas
Dr Basu discusses the “shadow curve” that could result from disruptions in cancer care during the COVID-19 pandemic and innovative strategies that...
S6 Ep24: Meyer Characterizes Current Approaches to Diagnosing, Managing, and Studying Cardiac Angiosarcoma
10 Jan 2022
Contributed by Lukas
Dr Meyer discusses the rarity of cardiac angiosarcoma, optimizing detection strategies, surgical interventions, and chemotherapy for this patient popu...
S6 Ep23: Dietz Draws Attention to Gender Disparities in Breast Cancer
06 Jan 2022
Contributed by Lukas
Dr Dietz discusses her experience as a woman in surgical oncology, the importance of bridging gender disparities, and her advice to women entering the...
S6 Ep22: Gilbert on Gaining New Ground at Vanderbilt
03 Jan 2022
Contributed by Lukas
Dr Gilbert discusses her new role as associate director for research, education, and professional development at Vanderbilt University Medical Center ...
S6 Ep21: Bardia on Sacituzumab Govitecan’s Current and Potential Future Position in TNBC
30 Dec 2021
Contributed by Lukas
Dr Bardia discusses the role of sacituzumab govitecan in the treatment of patients with metastatic triple-negative breast cancer, the influence of the...
S6 Ep21: Gasparetto Talks Management Strategies for Belantamab Mafodotin–Related Ocular Toxicity in Myeloma
27 Dec 2021
Contributed by Lukas
Dr Gasparetto discusses the management of ocular toxicities associated with belantamab mafodotin, the nuances of dose modification, and the potential ...
S6 Ep20: Phillips Reflects on Lessons Learned With BTK Inhibitors in MCL
23 Dec 2021
Contributed by Lukas
Dr Phillips discusses the utility of ibrutinib, acalabrutinib, and zanubrutinib in mantle cell lymphoma, the impact of long-term follow-up data with i...
S6 Ep19: Schwartzberg on Bringing Seminal Observations on AR From Bench to Bedside in ER+ Breast Cancer
20 Dec 2021
Contributed by Lukas
Dr. Schwartzberg discusses the rationale to evaluate enobosarm in AR-positive, ER-positive advanced breast cancer, phase 2 data with the agent, and ex...
S6 Ep18: Hochster Underscores Headway Made in Gastric/GEJ Cancers
16 Dec 2021
Contributed by Lukas
Dr. Hochster provides insight into the current gastric/GEJ landscape, spotlighting molecular testing approaches, the roles of chemoimmunotherapy combi...
S6 Ep17: Shah and Wang Share Insights Into Optimized CAR T-Cell Therapy in Hematologic Malignancies
13 Dec 2021
Contributed by Lukas
Dr. Shah and Dr. Wang discuss the management of cytokine release syndrome and neurotoxicity, the referral process, and the need for academic and commu...
S6 Ep16: Coombs Previews Anticipated ASH Abstracts in CLL
09 Dec 2021
Contributed by Lukas
Dr. Coombs discusses research that will be presented at the upcoming 2021 ASH Annual Meeting and Exposition in chronic lymphocytic leukemia, including...
S6 Ep15: FDA Approval Insights: Adjuvant Pembrolizumab in RCC
06 Dec 2021
Contributed by Lukas
Dr. Choueiri discusses the significance of the FDA approval of pembrolizumab as adjuvant therapy in renal cell carcinoma and key data from the pivotal...
S6 Ep14: Bleicher and Nardello Talk About Finding the Best Fit for Fellowship in Oncology
02 Dec 2021
Contributed by Lukas
Dr. Bleicher and Dr. Nardello discuss the process of finding a mentor, what to look for in a fellowship program, and the benefits of fellowship for bo...
S6 Ep13: Roychowdhury Relays Impact of Recent Infigratinib Approval in FGFR+ Cholangiocarcinoma
29 Nov 2021
Contributed by Lukas
Sameek Roychowdhury, MD, PhD, discusses the pivotal phase 2 trial with infigratinib in FGFR-positive cholangiocarcinoma, the safety and efficacy achie...
S6 Ep12: Katona Highlights the Hallmarks of Hereditary Diffuse Gastric Cancer
25 Nov 2021
Contributed by Lukas
Bryson Katona, MD, of Penn Medicine, discusses the hallmarks of hereditary diffuse gastric cancer.
S6 Ep11: Marvels in Medicine: Allison Talks Everything from Advances in Immunotherapy to Jamming With Willie Nelson
22 Nov 2021
Contributed by Lukas
Dr. Allison highlights everything from his proudest professional moments, to MD Anderson’s Moon Shot program, to his musical talents, to next steps ...
S6 Ep10: Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC
18 Nov 2021
Contributed by Lukas
Dr. Kalyan and Dr. Mouli discuss the importance of multidisciplinary care in hepatocellular carcinoma, data regarding real-world personalization treat...
S6 Ep9: Ku Reviews Exciting ESMO Data in Gastric/GEJ Cancer
15 Nov 2021
Contributed by Lukas
Dr. Ku underscores key takeaways from the CheckMate649 and DESTINY-Gastric02 trials in gastric/GEJ cancer and highlights ongoing research that has the...
S6 Ep8: Gradishar Gives Insight Into the Growing Role of SERDs in Breast Cancer
11 Nov 2021
Contributed by Lukas
Dr. Gradishar discusses the evolution of SERDs in breast cancer, novel SERDs that could shift the paradigm of breast cancer treatment, and ongoing res...
S6 Ep7: Tagawa Breaks Down FGFR Testing and the Use of Erdafitinib in Bladder Cancer
08 Nov 2021
Contributed by Lukas
Dr. Tagawa discusses the incidence and identification of FGFR alterations in bladder cancer, the approval and use of erdafitinib in the second-line se...
S6 Ep6: Yarchoan Talks Research Directions in Fibrolamellar Carcinoma
04 Nov 2021
Contributed by Lukas
Dr. Yarchoan underscores the unique characteristics of fibrolamellar carcinoma, treatment options for these patients, and ongoing research efforts to ...
S6 Ep5: FDA Approval Insights: Brexucabtagene Autoleucel in Relapsed/Refractory B-ALL
01 Nov 2021
Contributed by Lukas
Dr. Shah discusses the FDA approval of brexucabtagene autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia, key findings from the piv...
S6 Ep4: Jain and Spaggiari Speak to Surgical and Systemic Considerations for CRC Liver Metastases
28 Oct 2021
Contributed by Lukas
Dr. Jain and Dr. Spaggiari highlight key advancements in the treatment of patients with colorectal cancer liver metastases, patient and disease factor...
S6 Ep3: Johnson Previews the Potential Utility of VS-6766 Plus Defactinib in KRAS+ NSCLC
25 Oct 2021
Contributed by Lukas
In our exclusive interview, Johnson discussed the mechanism of action of VS-6766 alone and in combination with defactinib, expectations for the ongoin...
S6 Ep2: Abid on Optimizing COVID-19 Vaccines in CAR T-Cell Therapy Recipients
21 Oct 2021
Contributed by Lukas
Dr. Abid discusses immune-compromising factors that are indigenous to CAR T-cell therapy recipients, the immunogenic potential of different COVID-19 v...